Effect of pravastatin on chronic cardiac insufficiency in patients with ischemic cardiomyopathy

Objective To evaluate the effect of pravastatin on chronic cardiac insufficiency in patients with ischemic cardiomyopathy.Methods Totally 192 patients with ischemic cardiomyopathy complicating chronic cardiac insufficiency were randomly divided into 2 groups.Patients in control group(n=96)were administrated with conventional anti-heartfailure therapy for 27 weeks,and patients in treatment group(n=96) were added to pravastatin on the basis of control group.New York Heart Association (NYHA) functional classification,left ventricular ejection fraction(LVEF) and the level of amino-terminal pro-brain natriuretic peptide(NT-proBNP)were observed before and after treatment. Results After 27-week treatment,the total effective rates of treatment group and control group according to NYHA functional classification were 82.3% and 67.7% respectively. There was significant difference between two groups(P0.05). Compared with control group,the LVEF of treatment group increased significantly(P0.05)and the level of NT-proBNP decreased significantly(P0.05). No severe adverse reactions accured in both groups. Conclusion:Conventional pravastatin therapy can improve cardiac function in patients with ischemic cardiomyopathy complicating chronic cardiac insufficiency and can be used safely.